Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

MapLight Completes Dosing in Phase 1 Study for Social Deficit in Autism

americanpharmaceuticalreviewDecember 09, 2020

Tag: MapLight , ML-004 , ASD , Autism

PharmaSources Customer Service